Differentiating Omega-3 Fatty Acids from SPMs – Philip Calder, PhD, University of Southampton, UK
Presented at ASPEN CNW 2016 in Austin, Texas on January 18, 2016
Listen to the podcast below
Dr. Philip Calder’s presentation on the difference between SPMs and Omega-3 fatty acids is particularly important as researchers and clinicians learn more about inflammation and its prevention and resolution.
Omega-3 fatty acids are long chain & very long chain, highly unsaturated fatty acids • defined by the position of the methyl terminal double bond. They have different dietary sources and are metabolically related to each other. EPA, DPA, and DHA are poorly synthesized in humans so dietary sources are necessary. Increasing EPA+DHA intake increases the EPA and DHA content of blood lipids, blood cells, and many tissues including liver, heart & skeletal muscle, but the effect is dose, time and tissue dependent.
EPA and DHA give rise to pro-resolving mediators: Resolvins (E-series and D-series), Protectins (Neuroprotectins), and Maresins. These specialized pro-resolving mediators are inflammation resolving.